FDA Staff Questions Chiron Transplant Drug
From Reuters
Chiron Corp.’s experimental lung transplant drug Pulminiq failed to show that it reduced acute organ rejection in a small, limited clinical trial, Food and Drug Administration staff reviewers said in documents.
The trial showed that more patients taking the drug lived for two years, but without more data it wasn’t clear if that was a result of the drug, FDA staff said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
